secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001398733-25-000022
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive receives two new US patents for Anaphylm, extending protection to 2037
--------------------------------------------------------------------------------

- USPTO issued U.S. patent nos. 12,427,121 and 12,443,850 covering epinephrine prodrug compositions for sublingual film delivery.
- Patents expire May 4, 2037, subject to extensions; protect proprietary composition enabling oral film delivery.
- Anaphylm (dibutepinephrine) sublingual film, if FDA approved, would be first oral rescue treatment for severe allergic reactions.
- PDUFA target action date for Anaphylm is January 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873325000022/0001398733-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873325000022/aqst-20251008.htm
  HTML page:      https://secwatch.observer/filing/0001398733-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer